Market Cap 6.22M
Revenue (ttm) 0.00
Net Income (ttm) -7.97M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 250,800
Avg Vol 3,877,086
Day's Range N/A - N/A
Shares Out 2.86M
Stochastic %K 43%
Beta -2.09
Analysts Strong Sell
Price Target $17.00

Company Profile

Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections in the United States. The company's lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that is in Phase 2b clinical trial to treat patients with clostridium difficile infections. It also develops ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant st...

Industry: Biotechnology
Sector: Healthcare
Phone: 917 533 1469
Address:
259 Liberty Avenue, Staten Island, United States
EarningsInsider
EarningsInsider May. 12 at 1:00 PM
https://www.marketbeat.com/earnings/reports/2026-5-12-acurx-pharmaceuticals-inc-stock/ $ACXP Acurx Pharmaceuticals Earnings Transcript
0 · Reply
NotBornYesterday
NotBornYesterday May. 12 at 12:46 PM
0 · Reply
StocktwitsEarnings
StocktwitsEarnings May. 12 at 10:00 AM
$ACXP Q1 '26 Earnings Results & Recap • Reported GAAP EPS of -$0.62 up 71.16% YoY • On March 9, 2026, Acurx Pharmaceuticals announced a new clinical development initiative to expand the ibezapolstat program into recurrent C. difficile infection, with enrollment expected in the fourth quarter of this year.
0 · Reply
PUMPLESTILTSKIN
PUMPLESTILTSKIN May. 8 at 4:05 PM
0 · Reply
NotBornYesterday
NotBornYesterday May. 1 at 1:37 PM
$ACXP For the last several decades, the country ignored the deterioration of sustaining investments needed for the energy and mining industries. Recognition of those shortfalls has finally occurred and policy is changing. Not dissimilar, antimicrobial resistance has been ignored and is now an acute issue. Recognition and policy change is coming.
0 · Reply
StealthxPro
StealthxPro Apr. 30 at 2:33 PM
$ACXP to the moon 🌝
0 · Reply
NotBornYesterday
NotBornYesterday Apr. 30 at 1:00 PM
$ACXP So under what scenario would a former shareholder, who hasn't written the company off yet, decide to re-enter a position?
2 · Reply
Cpictures
Cpictures Apr. 28 at 4:10 PM
$ACXP Friendly reminder that this is not a real company. It is two old men that own patent collecting fat paychecks by diluting a few times a year. There is no lab. There is no research. There is no HQ. They pay two-bit media companies for interviews and press releases every so often to keep up appearances.
0 · Reply
NotBornYesterday
NotBornYesterday Apr. 28 at 12:48 PM
$ACXP BoD should authorize co to hold gold as treasury asset…and mgmt should start DCA’ing into it. Stagflation is here.
0 · Reply
newsfile_corp
newsfile_corp Apr. 27 at 12:00 PM
https://nfne.ws/294135 $ACXP #Energy #NASDAQ #Investing
0 · Reply
Latest News on ACXP
Acurx Pharmaceuticals Earnings Call Transcript: Q1 2026

May 12, 2026, 8:00 AM EDT - 1 day ago

Acurx Pharmaceuticals Earnings Call Transcript: Q1 2026


Acurx files to sell 1.65M shares of common stock for holders

2026-05-04T20:30:19.000Z - 8 days ago

Acurx files to sell 1.65M shares of common stock for holders


Acurx files to sell 1.3M shares of common stock for holders

2026-05-04T20:29:36.000Z - 8 days ago

Acurx files to sell 1.3M shares of common stock for holders


Acurx price target lowered to $10 from $20 at Alliance Global

2026-03-13T16:50:20.000Z - 2 months ago

Acurx price target lowered to $10 from $20 at Alliance Global


Acurx Pharmaceuticals Earnings Call Transcript: Q4 2025

Mar 13, 2026, 8:00 AM EDT - 2 months ago

Acurx Pharmaceuticals Earnings Call Transcript: Q4 2025


Acurx announces new ibezapolstat clinical trial program

2026-03-09T12:05:07.000Z - 2 months ago

Acurx announces new ibezapolstat clinical trial program


Acurx files to sell 750,000 shares of common stock for holders

2026-02-02T21:50:10.000Z - 3 months ago

Acurx files to sell 750,000 shares of common stock for holders


Acurx Pharmaceuticals Earnings Call Transcript: Q3 2025

Nov 12, 2025, 8:00 AM EST - 6 months ago

Acurx Pharmaceuticals Earnings Call Transcript: Q3 2025


Acurx announces publication of results from ibezapolstat study

2025-11-10T13:10:40.000Z - 6 months ago

Acurx announces publication of results from ibezapolstat study


Acurx files to sell 585,000 shares of common stock for holders

2025-10-20T21:30:17.000Z - 7 months ago

Acurx files to sell 585,000 shares of common stock for holders


Acurx granted new patent for DNA Polymerase IIIC Inhibitors

2025-10-09T11:36:04.000Z - 7 months ago

Acurx granted new patent for DNA Polymerase IIIC Inhibitors


Acurx target adjusted to $31 from $8 at H.C. Wainwright

2025-08-12T13:25:41.000Z - 9 months ago

Acurx target adjusted to $31 from $8 at H.C. Wainwright


Acurx Pharmaceuticals Earnings Call Transcript: Q2 2025

Aug 12, 2025, 8:00 AM EDT - 9 months ago

Acurx Pharmaceuticals Earnings Call Transcript: Q2 2025


Acurx Pharmaceuticals, Inc. Announces Reverse Stock Split

Jul 31, 2025, 9:25 AM EDT - 10 months ago

Acurx Pharmaceuticals, Inc. Announces Reverse Stock Split


Acurx Pharmaceuticals Earnings Call Transcript: Q1 2025

May 13, 2025, 8:00 AM EDT - 1 year ago

Acurx Pharmaceuticals Earnings Call Transcript: Q1 2025


Acurx Pharmaceuticals Earnings Call Transcript: Q4 2024

Mar 18, 2025, 8:00 AM EDT - 1 year ago

Acurx Pharmaceuticals Earnings Call Transcript: Q4 2024


Acurx Pharmaceuticals Earnings Call Transcript: Q3 2024

Nov 13, 2024, 8:00 AM EST - 1 year ago

Acurx Pharmaceuticals Earnings Call Transcript: Q3 2024


EarningsInsider
EarningsInsider May. 12 at 1:00 PM
https://www.marketbeat.com/earnings/reports/2026-5-12-acurx-pharmaceuticals-inc-stock/ $ACXP Acurx Pharmaceuticals Earnings Transcript
0 · Reply
NotBornYesterday
NotBornYesterday May. 12 at 12:46 PM
0 · Reply
StocktwitsEarnings
StocktwitsEarnings May. 12 at 10:00 AM
$ACXP Q1 '26 Earnings Results & Recap • Reported GAAP EPS of -$0.62 up 71.16% YoY • On March 9, 2026, Acurx Pharmaceuticals announced a new clinical development initiative to expand the ibezapolstat program into recurrent C. difficile infection, with enrollment expected in the fourth quarter of this year.
0 · Reply
PUMPLESTILTSKIN
PUMPLESTILTSKIN May. 8 at 4:05 PM
0 · Reply
NotBornYesterday
NotBornYesterday May. 1 at 1:37 PM
$ACXP For the last several decades, the country ignored the deterioration of sustaining investments needed for the energy and mining industries. Recognition of those shortfalls has finally occurred and policy is changing. Not dissimilar, antimicrobial resistance has been ignored and is now an acute issue. Recognition and policy change is coming.
0 · Reply
StealthxPro
StealthxPro Apr. 30 at 2:33 PM
$ACXP to the moon 🌝
0 · Reply
NotBornYesterday
NotBornYesterday Apr. 30 at 1:00 PM
$ACXP So under what scenario would a former shareholder, who hasn't written the company off yet, decide to re-enter a position?
2 · Reply
Cpictures
Cpictures Apr. 28 at 4:10 PM
$ACXP Friendly reminder that this is not a real company. It is two old men that own patent collecting fat paychecks by diluting a few times a year. There is no lab. There is no research. There is no HQ. They pay two-bit media companies for interviews and press releases every so often to keep up appearances.
0 · Reply
NotBornYesterday
NotBornYesterday Apr. 28 at 12:48 PM
$ACXP BoD should authorize co to hold gold as treasury asset…and mgmt should start DCA’ing into it. Stagflation is here.
0 · Reply
newsfile_corp
newsfile_corp Apr. 27 at 12:00 PM
https://nfne.ws/294135 $ACXP #Energy #NASDAQ #Investing
0 · Reply
NotBornYesterday
NotBornYesterday Apr. 23 at 5:03 PM
$ACXP Balance sheet is in best shape in 3+ years, cash runway has clear visibility to mid-2027, negative EV discounting doom, 9 figure sunk cost of establishing safety and Proof of Concept is in the past, re-introduction of Pasteur is no longer hope but fact. Meanwhile, the hate is palpable.
1 · Reply
RCInvestor
RCInvestor Apr. 23 at 4:15 PM
$ACXP will buy after 10 days from now
2 · Reply
MarketForecasting
MarketForecasting Apr. 23 at 4:01 PM
$ACXP *before the end of this week Trash bag of a company
0 · Reply
BankingBig
BankingBig Apr. 23 at 2:55 PM
$ACXP lmfao.. I buy this because it appeared to stable around 2.20 lmfao.. then drops another 10% I'm officially done ever touching this POS
0 · Reply
PUMPLESTILTSKIN
PUMPLESTILTSKIN Apr. 23 at 2:23 PM
$ACXP drop 80 cents and another all time low will be made. will probably take 2 weeks at the current rate. Unless Luci does another pr blitz and fakes out a bunch of newbies.
1 · Reply
BankingBig
BankingBig Apr. 22 at 7:45 PM
$ACXP back in for a small bite here
0 · Reply
MarketForecasting
MarketForecasting Apr. 22 at 7:14 PM
$ACXP this will be under 2 dollars before the end of next week .
1 · Reply
ChicagoJoe20
ChicagoJoe20 Apr. 22 at 1:56 PM
$ACXP C.DIff cost hospitals a lot of money. Medicare pays for this too. Why isn't the Government funding this?
1 · Reply
PUMPLESTILTSKIN
PUMPLESTILTSKIN Apr. 21 at 6:34 PM
0 · Reply
focafoca99
focafoca99 Apr. 16 at 8:31 PM
$ACXP closed a registered direct offering with about $2.5 million upfront and potential additional proceeds from short-term warrant exercises.
0 · Reply
PUMPLESTILTSKIN
PUMPLESTILTSKIN Apr. 16 at 8:26 PM
$ACXP Another Dilution. 400K per year for Luci to incinerate shareholders. Between the IPO and the may offerings, Luci destroyed ~ $32 M to enroll 32 patients. He spent about $1M per patient. He would argue that the money was spent on other operations, sales activities, etc. But the truth is that ZERO was accomplished outside the 32 enrolled patients. They got nothing done. They won zero grants, they found zero buyers, they created zero partnerships, they created zero assets. Luci will now pretend that $7M is enough to finish this new 20 patient study. It is not. It is enough to keep the lights on for another 18 months, and pay the skeleton crew a king's ransom for doing nothing. I predict announcement of 3 patients enrolled by November 2027, followed by liquidation. Luci has it set up perfectly squeeze the last few drops of blood out of this emaciated corpse of a company.
3 · Reply
RenDragon
RenDragon Apr. 16 at 4:39 PM
$ACXP so more dilution for what exactly? Not enough to run a phase 3, but enough to keep the bro’s on the gravy train for another few years.
1 · Reply